Vol 3, No 4 (2017)
Review paper
Published online: 2018-01-22
Układ dopełniacza w chorobach autoimmunologicznych
Forum Reumatol 2017;3(4):205-210.
Abstract
Układ dopełniacza odgrywa rolę istotną rolę w obronie organizmu i regulacji układu immunologicznego. Jego aktywacja zachodzi za pośrednictwem drogi klasycznej, alternatywnej i lektynowej. Zaburzone działanie tego układu zaobserwowano w wielu chorobach z kręgu autoimmunizacji. W artykule omówiono zasady funkcjonowania układu dopełniacza, jego potencjalną rolę w patogenezie i obrazie klinicznym wybranych chorób autoimmunologicznych oraz wskazano na możliwości terapeutyczne chorób, w patogenezie których uczestniczy ten układ.
Keywords: układ dopełniaczaautoimmunizacja
References
- Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016; 12(7): 383–401.
- Jakóbisiak M, Gołąb J. Układ dopełniacza. Immunologia. 2008: 66–77.
- Walport MJ, Walport MJ. Complement. First of two parts. N Engl J Med. 2001; 344(14): 1058–1066.
- Ballanti E, Perricone C, Greco E, et al. Complement and autoimmunity. Immunol Res. 2013; 56(2-3): 477–491.
- Davis AE, Davis AE, Davis AE. The pathophysiology of hereditary angioedema. Clin Immunol. 2005; 114(1): 3–9.
- Józsi M, Reuter S, Nozal P, et al. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. Immunol Lett. 2014; 160(2): 163–171.
- Parker CJ. Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. Hematology Am Soc Hematol Educ Program. 2011; 2011: 21–29.
- Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res . 2002; 4(Suppl. 3): S279–293.
- Lintner KE, Wu YL, Yang Y, et al. Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases. Front Immunol. 2016; 7: 36.
- Chen M, Daha MR, Kallenberg CGM. The complement system in systemic autoimmune disease. J Autoimmun. 2010; 34(3): J276–J286.
- Merle NS, Noe R, Halbwachs-Mecarelli L, et al. Complement System Part II: Role in Immunity. Front Immunol. 2015; 6: 257.
- Walport MJ. Complement. Second of two parts. N Engl J Med. 2001; 344(15): 1140–1144.
- Li Na, Zhang J, Liao D, et al. Association between C4, C4A, and C4B copy number variations and susceptibility to autoimmune diseases: a meta-analysis. Sci Rep. 2017; 7: 42628.
- Carroll MC. The role of complement in B cell activation and tolerance. Adv Immunol. 2000; 74: 61–88.
- Prodeus AP, Goerg S, Shen LM, et al. A critical role for complement in maintenance of self-tolerance. Immunity. 1998; 9(5): 721–731.
- Walport MJ, Lachmann PJ. Erythrocyte complement receptor type 1, immune complexes, and the rheumatic diseases. Arthritis Rheum. 1988; 31(2): 153–158.
- Kalunian KC, Chatham WW, Massarotti EM, et al. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum. 2012; 64(12): 4040–4047.
- Orbai AM, Truedsson L, Sturfelt G, et al. Anti-C1q antibodies in systemic lupus erythematosus. Lupus. 2015; 24(1): 42–49.
- Aydogan K, Karadogan SK, Adim SB, et al. Hypocomplementemic urticarial vasculitis: a rare presentation of systemic lupus erythematosus. Int J Dermatol. 2006; 45(9): 1057–1061.
- Sinico RA, Rimoldi L, Radice A, et al. Anti-C1q autoantibodies in lupus nephritis. Ann N Y Acad Sci. 2009; 1173: 47–51.
- Hietala MA, Jonsson IM, Tarkowski A, et al. Complement deficiency ameliorates collagen-induced arthritis in mice. J Immunol. 2002; 169(1): 454–459.
- Wang Y, Rollins SA, Madri JA, et al. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci U S A. 1995; 92(19): 8955–8959.
- Neumann E, Barnum SR, Tarner IH, et al. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 2002; 46(4): 934–945.
- Al M.A.S.E. T. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23(5): 581–590.
- Hudson M, Walker JG, Fritzler M, et al. Hypocomplementemia in systemic sclerosis--clinical and serological correlations. J Rheumatol. 2007; 34(11): 2218–2223.
- Oku K, Atsumi T, Bohgaki M, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis. 2009; 68(6): 1030–1035.
- Samarkos M, Mylona E, Kapsimali V. The role of complement in the antiphospholipid syndrome: a novel mechanism for pregnancy morbidity. Semin Arthritis Rheum. 2012; 42(1): 66–69.
- Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004; 10(11): 1222–1226.
- Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006; 65(6): 796–803.
- Ramos-Casals M, Brito-Zerón P, Yagüe J, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford). 2005; 44(1): 89–94.
- Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003; 362(9388): 971–982.
- Briani C, Doria A, Sarzi-Puttini P, et al. Update on idiopathic inflammatory myopathies. Autoimmunity. 2006; 39(3): 161–170.
